Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret A.S. (GENIL.IS)

Saturday

8:13 PM

ThesisThe recent partnerships and successful product launches are expected to drive revenue growth, enhancing investor sentiment.

Revenue Outlook

Metric	FY2024	FY2025
Revenue	$19.3B	$19.2B
Rev. Growth	+63.9%	-0.6%
EPS	$0.04	$0.15
EPS Growth	-71.2%	+247%
P/E	276.9×	79.7×

What’s Driving the Stock

01Recent partnerships with local hospitals have increased access to a broader patient base, potentially boosting revenue by 15% in the next year.
02Successful launch of a new generic drug expected to capture 10% market share within the first year.
03Cost reduction initiatives projected to improve gross margins by 3% over the next two quarters.
04Growth in the Turkish healthcare market
05Increasing demand for affordable generic medications
06Regulatory approvals for new drug formulations
07Market share gains in the Turkish pharmaceutical sector
08Pricing dynamics in the generic drug market

FY2025 Snapshot

Revenue: $19.2B
Rev. Growth: -0.6%
Gross Margin: 21.0%
Op. Margin: 12.9%
Net Margin: 4.2%
Net Income: $814M
NI Growth: +319%
EPS: $0.15
1Y Return: +4.5%

My Notes

"We are committed to expanding our market presence and delivering value through innovative solutions."
Moat: Gen Ilac's competitive advantage lies in its established relationships with healthcare providers and a strong portfolio of generic drugs.
growth - Investors may be drawn to Gen Ilac's potential for revenue growth through product expansion and market penetration.
Interest rates can impact Gen Ilac's financing costs for R&D and capital expenditures…
Watch on earnings: Turkish pharmaceutical market growth rate, Regulatory approval timelines for new drugs, Generic drug pricing trends.

One Sentence Summary:

Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret A.S.: the setup is constructive — recent partnerships with local hospitals have increased access to a broader patient base.

Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.

Writing up the research noteFirst read for a new ticker takes about 20-30 seconds while we build the analysis from the latest fundamentals, estimates, and intelligence. It's saved after this, so future visits are instant.